Vlad Vitoc Purchases 72,700 Shares of MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) CEO Vlad Vitoc acquired 72,700 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were purchased at an average cost of $1.39 per share, with a total value of $101,053.00. Following the transaction, the chief executive officer directly owned 976,121 shares of the company’s stock, valued at $1,356,808.19. This trade represents a 8.05% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

MAIA Biotechnology Stock Up 5.9%

MAIA opened at $1.43 on Thursday. MAIA Biotechnology, Inc. has a twelve month low of $0.87 and a twelve month high of $3.19. The company has a 50-day simple moving average of $1.32 and a 200 day simple moving average of $1.53. The stock has a market capitalization of $86.94 million, a price-to-earnings ratio of -2.13 and a beta of 0.23.

MAIA Biotechnology (NYSEAMERICAN:MAIA) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.04. Sell-side analysts anticipate that MAIA Biotechnology, Inc. will post -0.52 EPS for the current fiscal year.

Institutional Investors Weigh In On MAIA Biotechnology

Several institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its holdings in shares of MAIA Biotechnology by 3.6% in the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after acquiring an additional 7,746 shares during the last quarter. Marshall Wace LLP bought a new position in shares of MAIA Biotechnology in the second quarter worth about $29,000. Jane Street Group LLC bought a new position in shares of MAIA Biotechnology in the second quarter worth about $52,000. Ritholtz Wealth Management bought a new position in shares of MAIA Biotechnology in the fourth quarter worth about $35,000. Finally, Centric Wealth Management lifted its holdings in shares of MAIA Biotechnology by 2.0% in the fourth quarter. Centric Wealth Management now owns 586,398 shares of the company’s stock worth $897,000 after acquiring an additional 11,500 shares during the last quarter. Institutional investors own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.